Introduction

Non-alcoholic fatty liver disease (NAFLD) and irritable bowel syndrome (IBS) are the two most common gastrointestinal disorders in the general population, presenting significant challenges to healthcare systems and impacting the quality of life for millions of people. Some studies highlight a direct link between both since there are common mechanisms involved in many of the local and systemic manifestations of NAFLDs and IBS leading to shared risk factors. 

Shared risk factors such as obesity, insulin resistance, inflammation, and dysbiosis could indicate common underlying pathways contributing to both conditions ¹. Additionally, lifestyle and dietary choices that affect one condition might similarly impact the other. 

The interrelationship between these two conditions remains an area of active research, with a growing interest in understanding how they might influence each other, the implications for patient management, and potential treatment strategies. 

This article aims to provide a comprehensive exploration of both NAFLD and IBS, delving into their individual characteristics and examining the connections between them. Understanding these connections will help guide healthcare providers in delivering effective care and support to those affected by these chronic conditions.

Non-alcoholic fatty liver disease

NAFLD is a broad term that refers to a range of liver conditions characterised by an excessive accumulation of fat in liver cells (hepatocytes) which was not caused by alcohol consumption, with or without liver inflammation. NAFLD is the most common liver disorder in Western countries and is increasingly prevalent worldwide, largely due to rising rates of obesity, type II diabetes and metabolic syndrome.² The spectrum of conditions includes simple steatosis and nonalcoholic steatohepatitis. Simple steatosis involves the buildup of fat in the liver without significant inflammation or liver cell damage. In this stage, the condition is often asymptomatic and may be detected incidentally during routine blood tests or imaging studies. A more severe form of NAFLD is NASH, characterised by liver inflammation and cell damage in addition to fat accumulation. NASH can progress to more severe liver diseases. If left unmanaged, NAFLD can progress to NASH, a condition that significantly increases the risk of developing advanced liver complications including fibrosis, cirrhosis, and hepatocellular carcinoma.² The global prevalence was estimated to be about 24 %.³ It is predicted to become the most frequent indication for liver transplantation by 2030.⁴

Irritable bowel syndrome

Irritable Bowel Syndrome (IBS) is a common condition characterised by abdominal discomfort associated with altered bowel movements, accompanied by changes in bowel habits such as diarrhoea, constipation, or both. It affects 7 % to 21% of the general population and is a chronic condition that can reduce the quality of life and work.⁵ It involves dysfunction in gut-brain communication, altered gut motility, and heightened sensitivity to bowel stimuli. The common symptoms include recurring abdominal pain or discomfort, often relieved by bowel movements, changes in bowel habits (diarrhoea, constipation, or alternating between both), bloating and gas, a sense of incomplete evacuation after bowel movements, and mucus in the stool. Other symptoms may include nausea, indigestion, and fatigue, though these are less common. Symptoms can vary in intensity and frequency and are often exacerbated by stress, certain foods, or other environmental triggers.

Subtypes

According to Rome III, IBS was divided based on the proportion of all bowel movements that were loose/watery or hard/lumpy.⁶

IBS with Constipation (IBS-C): Infrequent bowel movements, hard or lumpy stools, and discomfort during defecation, mostly constipation and abdominal discomfort.

IBS with Diarrhoea (IBS-D): Involves frequent, loose, or watery stools, often with a sense of urgency, simply diarrhoea, and abdominal discomfort.

IBS with Mixed Bowel Habits (IBS-M): Alternating patterns of constipation and diarrhoea with abdominal discomfort.

IBS Unsubtyped (IBS-U): Symptoms vary, do not fit neatly into the other three categories, with variable bowel habits that do not consistently align with any specific pattern.

Common risk factors of NAFLD and IBS

The development of NAFLD is often linked to a variety of lifestyle and metabolic factors, as well as certain health conditions. Common risk factors include obesity, insulin resistance, type II diabetes, high cholesterol and triglycerides, metabolic syndrome, sedentary lifestyle and poor disease.⁷

IBS is influenced by a range of factors that affect gastrointestinal health and the gut-brain axis which includes stress and anxiety, gut microbiota imbalance, infections, food sensitivities and intolerance, family history and hormonal changes. 

Though NAFLD and IBS affect different parts of the digestive system, there are several shared risk factors suggesting a possible connection between the two. They are obesity, diet and nutrition, sedentary lifestyle, inflammation, stress and anxiety and gut microbiota.⁸

Clinical presentation

NAFLD often has a silent onset, with many individuals remaining asymptomatic for years. When symptoms do occur, they may include fatigue and weakness, general feelings of tiredness and reduced energy are common in advanced stages. The symptoms include dull or aching pain in the right upper quadrant of the abdomen, hepatomegaly, and jaundice. Fibrosis, or cirrhosis, can present with more severe symptoms, including ascites, oedema, gastrointestinal bleeding, hepatic encephalopathy, and other complications. Irritable bowel syndrome presents with a range of gastrointestinal symptoms, often fluctuating in severity and frequency. Common symptoms include abdominal pain and discomfort, changes in bowel habits, bloating and gas, and mucus in stool.

Pathophysiology

The potential link between NAFLD and IBS involves common underlying mechanisms and shared risk factors. These links suggest that there could be a relationship between liver health and gastrointestinal function. 

The pathophysiology of NAFLD involves a complex interplay of metabolic, hormonal, and inflammatory processes, leading to the accumulation of fat in the liver and its potential progression to more severe conditions. The first type of NAFLD has a narrow relationship with metabolic syndrome and current beliefs are that insulin resistance is the primary pathophysiology mechanism. The second type of NAFLD is a relationship with infectious pathologies that can lead to liver steatosis; for example, hepatitis C and HIV can be caused by specific medication and specific toxins or inherited/acquired metabolic disease.⁹ 

The pathophysiology of IBS is complex and multifactorial, involving the gut-brain axis, intestinal motility, and gut microbiota.¹⁰ Both NAFLD and IBS can be involved in the inflammatory processes. In NAFLD, inflammation is primarily in the liver, while in IBS, low-grade inflammation occurs in the gut. A common inflammatory pathway may link these conditions. 

Dysbiosis plays a role in both NAFLD and IBS. Altered gut microbiota can contribute to inflammation and metabolic imbalances, potentially influencing NAFLD and gut function. Poor dietary habits and a sedentary lifestyle contribute to both NAFLD and IBS. Common dietary factors, like high sugar and fat intake, may influence the pathophysiology of both conditions.

Diagnostic approaches

Diagnosis of NAFLD involves a combination of clinical evaluation, laboratory tests, and imaging studies. The common diagnostic approaches include liver function tests (LFT) for the evaluation of elevated liver enzymes alanine transaminase and aspartate transaminase, ultrasound imaging and other imaging techniques like CT, MRI, and transient elastography (FibroScan) may be used to assess liver fat content and fibrosis. 

The liver biopsy is the gold standard for diagnosing NASH and assessing the severity of liver damage. However, it's invasive and typically reserved for complex cases or when other methods are inconclusive. 

Diagnostic approaches for IBS are primarily clinical, based on symptom patterns and exclusion of other gastrointestinal conditions. Rome IV criteria is a widely used set of criteria requiring recurrent abdominal pain at least once a week for the past three months, along with other symptom-based criteria¹¹. 

Other tests include stool tests, endoscopy and colonoscopy.

Diagnosing both NSAID and IBS can be challenging due to several factors, asymptomatic presentation making early detection difficult. The symptoms of NAFLD and IBS can overlap with other gastrointestinal and liver diseases, complicating the diagnostic process. Though the liver biopsy is the gold standard for diagnosing it is not always feasible for all patients. IBS relies heavily on patient-reported symptoms, which can be subjective and variable, leading to inconsistent diagnoses.

Approaches for managing NAFLD and IBS

Managing non-alcoholic fatty liver disease and irritable bowel syndrome simultaneously requires a comprehensive and integrated approach, addressing common risk factors and specific challenges posed by both conditions.

Lifestyle modifications

A balanced diet, including a diet rich in fruits, vegetables, whole grains, and lean proteins can benefit both conditions. A Mediterranean-style diet, defined as reduced carbohydrate intake (especially sugars and refined carbohydrates) and increased monounsaturated and omega-3 fatty acid intake, can reduce liver fat and thus positively contribute to the management of NAFLD.¹² 

Other studies show that caffeine is a strong antioxidant that could help to reduce the burden of liver inflammation and may provide hepatoprotective effects.¹³ For IBS, a low-FODMAP diet can help reduce bloating and gastrointestinal discomfort. Minimising refined sugars and saturated fats can help manage both conditions, reducing liver fat in NAFLD and gastrointestinal distress in IBS. 

Weight Management: gradual weight loss through a combination of diet and exercise is beneficial. Moderate physical activity, such as walking, cycling, or swimming, is recommended. Exercise improves insulin sensitivity and overall health, benefiting both liver and gut function. Since stress can exacerbate both NAFLD and IBS, techniques like yoga, meditation, deep breathing, and cognitive behavioural therapy can be helpful. Ensuring sufficient sleep is crucial for managing stress and promoting overall health.

Medical management

Insulin-sensitising medication has been the cornerstone of NASH medical treatment for several years. These drugs can also have indirect benefits for IBS by addressing metabolic imbalances. Fat-soluble compounds like vitamin E prevent liver injury by protecting against mitochondrial toxicity.¹⁴ Antispasmodics and antidiarrheals can help manage IBS symptoms without impacting NAFLD treatment. Probiotics, prebiotics, and dietary adjustments can help restore gut health, potentially benefiting liver health as well.

Monitoring and follow-up

Monitoring liver health through regular liver function tests is essential for tracking NAFLD progression. If necessary, these procedures can help assess IBS and exclude other gastrointestinal conditions. Given the complexity of managing both conditions, a multidisciplinary team including gastroenterologists, hepatologists, nutritionists, and mental health professionals can offer comprehensive care. Educating patients about the relationship between NAFLD and IBS and providing support for lifestyle changes can improve adherence to treatment plans.

Summary

Non-alcoholic fatty liver disease and irritable bowel syndrome are conditions with different pathophysiologies but share common risk factors. Both conditions can be challenging to diagnose and treat due to overlapping symptoms and variable presentations. Managing both NAFLD and IBS simultaneously requires a holistic approach that addresses underlying risk factors and incorporates lifestyle modifications, medical management, and collaborative care. This integrated approach aims to manage both conditions effectively, promoting improved liver and gut health and enhancing the patient's quality of life.